Daiichi Sankyo to tap Ranbaxy arm for Mexican entry
This article was originally published in Scrip
Daiichi Sankyo continues to tap into the synergies provided by its acquisition of Ranbaxy Laboratories.
You may also be interested in...
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…
Eisai and partner Sun to take lorcaserin off the Indian market. It remains to be seen whether the Japanese firm sees merit in pursuing a simmering patent infringement suit against Dr Reddy’s, which may need to review its own plans for lorcaserin.